Comprehensive Stock Comparison
Compare Enhabit, Inc. (EHAB) vs HCA Healthcare, Inc. (HCA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | HCA | 7.1% revenue growth vs EHAB's -1.1% |
| Value | HCA | Lower P/E (17.5x vs 22.5x) |
| Quality / Margins | HCA | 9.0% net margin vs EHAB's -1.1% |
| Stability / Safety | HCA | Beta 0.29 vs EHAB's 0.56 |
| Dividends | HCA | 0.6% yield; 5-year raise streak; EHAB pays no meaningful dividend |
| Momentum (1Y) | HCA | +73.9% vs EHAB's +62.6% |
| Efficiency (ROA) | HCA | 11.2% ROA vs EHAB's -1.0%, ROIC 19.9% vs -7.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Enhabit operates a network of home health and hospice care agencies across the United States, providing skilled nursing, therapy services, and end-of-life care to patients in their homes. The company generates revenue primarily from Medicare reimbursements — which account for the vast majority of its income — along with payments from Medicaid, private insurers, and patients. Its competitive advantage lies in its extensive geographic footprint across 34 states, which creates referral network effects and operational scale in a fragmented industry.
HCA Healthcare is one of the largest for-profit hospital operators in the United States, providing comprehensive medical and surgical services through its network of acute care hospitals and outpatient facilities. It generates revenue primarily from patient services — including inpatient hospital stays, outpatient procedures, and emergency care — with the vast majority coming from government programs like Medicare and Medicaid alongside private insurance reimbursements. The company's scale advantage — operating over 180 hospitals concentrated in high-growth markets — creates significant purchasing power with suppliers and negotiating leverage with payers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
HCA leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). EHAB leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
HCA is the larger business by revenue, generating $75.6B annually — 72.2x EHAB's $1.0B. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to EHAB's -1.1%.
| Metric | EHABEnhabit, Inc. | HCAHCA Healthcare, I… |
|---|---|---|
| RevenueTrailing 12 months | $1.0B | $75.6B |
| EBITDAEarnings before interest/tax | $34M | $15.5B |
| Net IncomeAfter-tax profit | -$12M | $6.8B |
| Free Cash FlowCash after capex | $58M | $7.7B |
| Gross MarginGross profit ÷ Revenue | +48.4% | +41.5% |
| Operating MarginEBIT ÷ Revenue | +0.8% | +15.8% |
| Net MarginNet income ÷ Revenue | -1.1% | +9.0% |
| FCF MarginFCF ÷ Revenue | +5.5% | +10.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.9% | +6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +110.0% | +44.6% |
Valuation Metrics
| Metric | EHABEnhabit, Inc. | HCAHCA Healthcare, I… |
|---|---|---|
| Market CapShares × price | $686M | $118.5B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $167.6B |
| Trailing P/EPrice ÷ TTM EPS | -4.38x | 18.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.50x | 17.50x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.89x |
| EV / EBITDAEnterprise value multiple | — | 10.82x |
| Price / SalesMarket cap ÷ Revenue | 0.66x | 1.57x |
| Price / BookPrice ÷ Book value/share | 1.23x | — |
| Price / FCFMarket cap ÷ FCF | 14.47x | 15.40x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs EHAB's 4/9, reflecting strong financial health.
| Metric | EHABEnhabit, Inc. | HCAHCA Healthcare, I… |
|---|---|---|
| ROE (TTM)Return on equity | -2.0% | — |
| ROA (TTM)Return on assets | -1.0% | +11.2% |
| ROICReturn on invested capital | -7.3% | +19.9% |
| ROCEReturn on capital employed | -9.6% | +27.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.03x | — |
| Net DebtTotal debt minus cash | $541M | $49.2B |
| Cash & Equiv.Liquid assets | $28M | $1.0B |
| Total DebtShort + long-term debt | $570M | $50.2B |
| Interest CoverageEBIT ÷ Interest expense | 0.93x | 5.37x |
Total Returns (with DRIP)
A $10,000 investment in HCA five years ago would be worth $30,878 today (with dividends reinvested), compared to $5,444 for EHAB. Over the past 12 months, HCA leads with a +73.9% total return vs EHAB's +62.6%. The 3-year compound annual growth rate (CAGR) favors HCA at 30.2% vs EHAB's -3.9% — a key indicator of consistent wealth creation.
| Metric | EHABEnhabit, Inc. | HCAHCA Healthcare, I… |
|---|---|---|
| YTD ReturnYear-to-date | +49.7% | +12.6% |
| 1-Year ReturnPast 12 months | +62.6% | +73.9% |
| 3-Year ReturnCumulative with dividends | -11.3% | +120.8% |
| 5-Year ReturnCumulative with dividends | -45.6% | +208.8% |
| 10-Year ReturnCumulative with dividends | -45.6% | +688.3% |
| CAGR (3Y)Annualised 3-year return | -3.9% | +30.2% |
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than EHAB's 0.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EHAB currently trades 99.8% from its 52-week high vs HCA's 95.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EHABEnhabit, Inc. | HCAHCA Healthcare, I… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.56x | 0.29x |
| 52-Week HighHighest price in past year | $13.64 | $552.90 |
| 52-Week LowLowest price in past year | $6.47 | $295.00 |
| % of 52W HighCurrent price vs 52-week peak | +99.8% | +95.8% |
| RSI (14)Momentum oscillator 0–100 | 84.1 | 56.0 |
| Avg Volume (50D)Average daily shares traded | 419K | 879K |
Analyst Outlook
Wall Street rates EHAB as "Hold" and HCA as "Buy". Consensus price targets imply -0.6% upside for EHAB (target: $14) vs -1.1% for HCA (target: $524). HCA is the only dividend payer here at 0.56% yield — a key consideration for income-focused portfolios.
| Metric | EHABEnhabit, Inc. | HCAHCA Healthcare, I… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $13.53 | $523.92 |
| # AnalystsCovering analysts | 11 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | +0.6% |
| Dividend StreakConsecutive years of raises | 0 | 5 |
| Dividend / ShareAnnual DPS | — | $2.94 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +8.5% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 22 | Feb 26 | Change |
|---|---|---|---|
| Enhabit, Inc. (EHAB) | 100 | 43.08 | -56.9% |
| HCA Healthcare, Inc. (HCA) | 100 | 283.82 | +183.8% |
HCA Healthcare, Inc. (HCA) returned +209% over 5 years vs Enhabit, Inc. (EHAB)'s -46%. A $10,000 investment in HCA 5 years ago would be worth $30,878 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Enhabit, Inc. (EHAB) | $1.1B | $1.0B | -4.0% |
| HCA Healthcare, Inc. (HCA) | $41.5B | $75.6B | +82.2% |
HCA Healthcare, Inc.'s revenue grew from $41.5B (2016) to $75.6B (2025) — a 6.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Enhabit, Inc. (EHAB) | 7.0% | -15.1% | -317.0% |
| HCA Healthcare, Inc. (HCA) | 7.0% | 9.0% | +28.8% |
HCA Healthcare, Inc.'s net margin went from 7% (2016) to 9% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| HCA Healthcare, Inc. (HCA) | 14.8 | 16.5 | +11.5% |
HCA Healthcare, Inc. has traded in a 12x–17x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Enhabit, Inc. (EHAB) | 19.23 | -3.11 | -116.2% |
| HCA Healthcare, Inc. (HCA) | 7.3 | 28.38 | +288.8% |
HCA Healthcare, Inc.'s EPS grew from $7.30 (2016) to $28.38 (2025) — a 16% CAGR.
Chart 6Free Cash Flow — 5 Years
Enhabit, Inc. generated $47M FCF in 2024 (-60% vs 2021). HCA Healthcare, Inc. generated $8B FCF in 2025 (+43% vs 2021).
EHAB vs HCA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is EHAB or HCA a better buy right now?
HCA Healthcare, Inc. (HCA) offers the better valuation at 18.7x trailing P/E (17.5x forward), making it the more compelling value choice. Analysts rate HCA Healthcare, Inc. (HCA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EHAB or HCA?
On forward P/E, HCA Healthcare, Inc. is actually cheaper at 17.5x.
03Which is the better long-term investment — EHAB or HCA?
Over the past 5 years, HCA Healthcare, Inc. (HCA) delivered a total return of +208.8%, compared to -45.6% for Enhabit, Inc. (EHAB). A $10,000 investment in HCA five years ago would be worth approximately $31K today (assuming dividends reinvested). Over 10 years, the gap is even starker: HCA returned +688.3% versus EHAB's -45.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EHAB or HCA?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc. (HCA) is the lower-risk stock at 0.29β versus Enhabit, Inc.'s 0.56β — meaning EHAB is approximately 93% more volatile than HCA relative to the S&P 500.
05Which has better profit margins — EHAB or HCA?
HCA Healthcare, Inc. (HCA) is the more profitable company, earning 9.0% net margin versus -15.1% for Enhabit, Inc. — meaning it keeps 9.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCA leads at 15.8% versus -11.1% for EHAB. At the gross margin level — before operating expenses — EHAB leads at 48.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EHAB or HCA more undervalued right now?
On forward earnings alone, HCA Healthcare, Inc. (HCA) trades at 17.5x forward P/E versus 22.5x for Enhabit, Inc. — 5.0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EHAB: -0.6% to $13.53.
07Which pays a better dividend — EHAB or HCA?
In this comparison, HCA (0.6% yield) pays a dividend. EHAB does not pay a meaningful dividend and should not be held primarily for income.
08Is EHAB or HCA better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc. (HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.29), 0.6% yield, +688.3% 10Y return). Both have compounded well over 10 years (HCA: +688.3%, EHAB: -45.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EHAB and HCA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. HCA pays a dividend while EHAB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.